Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 107 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eicosapentaenoic Acid Clear all
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

NCT01154985
View directory record Official record
Conditions
Steatohepatitis
Interventions
Placebo capsule, EPA-E 300 mg capsule
Drug
Lead sponsor
Mochida Pharmaceutical Company, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

NCT00440050
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
DHA (Docosahexaenoic Acid), Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Fish Oil Brain Delivery Study

NCT02541929
View directory record Official record
Conditions
Brain Health
Interventions
Docosahexaenoic acid
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 6, 2026, 10:54 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

NCT04417257
View directory record Official record
Conditions
COVID-19 Disease
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Chandler, Arizona • Newport Beach, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 6, 2026, 10:54 AM EDT
Not listed Phase 2 Interventional

An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels

NCT02052986
View directory record Official record
Conditions
Dyslipidemia
Interventions
VASCAZEN
Other
Lead sponsor
New York Hospital Queens
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Fresh Meadows, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1 Interventional

Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy

NCT00060749
View directory record Official record
Conditions
Macular Degeneration
Interventions
Docosahexaenoic Acid (DHA) Dietary Supplement
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omega 3 Fatty Acid Trial

NCT00586222
View directory record Official record
Conditions
Omega-3 Fatty Acids, Pediatric Bipolar Disorder, Adolescent Bipolar Disorder, Magnetic Resonance Spectroscopy Imaging
Interventions
Omega-3 Fatty Acid, Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Nutritional Intervention to Prevent Diabetes

NCT00333554
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
DHA Treatment, Placebo for DHA
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 5 Months
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

NCT00001146
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Ethyl Eicosapentaenoic Acid, OmegaBrite
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 10:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cross-sectional Survey of Omega-3 Fatty Acid Blood Levels

NCT02883764
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 6, 2026, 10:54 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 6, 2026, 10:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Synergy Between Choline and DHA

NCT03194659
View directory record Official record
Conditions
Pregnancy
Interventions
Choline
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

NCT01208961
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans

NCT02472171
View directory record Official record
Conditions
Inflammation
Interventions
High saturated fat meal, placebo powder and sunflower oil, High saturated fat meal, blueberry powder and sunflower oil, High saturated fat meal, placebo powder and DHA
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

NCT01154400
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Casein protein hydrolysates, Whey protein hydrolysates, Casein protein hydrolysates + LEU, Whey protein hydrolysates + LEU
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 3 Interventional

Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression

NCT00096798
View directory record Official record
Conditions
Depressive Disorder, Depression
Interventions
Ethyl-eicosapentanoic acid (ethyl-EPA)
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Study Products Containing Varying Quantities of Docosahexaenoic Acid (DHA)

NCT01174134
View directory record Official record
Conditions
Levels of DHA in the Blood
Interventions
Nutritional beverage
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
18 Months to 36 Months
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

NCT04198805
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions
Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo
Dietary Supplement · Combination Product · Other
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

NCT00278135
View directory record Official record
Conditions
Age-Related Cognitive Decline, Age-Related Memory Disorders
Interventions
DHA (nutritional supplement) or placebo
Dietary Supplement
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
55 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA + DHA in a SMEDS Formulation

NCT03443076
View directory record Official record
Conditions
Bioavailability
Interventions
EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved)
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Boca Raton, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 6, 2026, 10:54 AM EDT